VivoSeq
Oncology

Recurrent Glioblastoma

5

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Recurrent Glioblastoma is an early-stage landscape with 5 programs across 1 company. The most active players are AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 71% of 7 pipeline programs.

Analysis

Trial Status

3

clinical trials

Active, not recruiting2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·Preclinical·NCT07416188·40 enrolled
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02974621·70 enrolled
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT04214392·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)